GTH 2021 State of the Art—Cardiac Surgery: The Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery

Laura Ranta; Emmanuelle Scala

doi:10.1055/a-1336-6116

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 2021; 41(01): 059-062
DOI: 10.1055/a-1336-6116

Review Article

GTH 2021 State of the Art—Cardiac Surgery: The Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery

Laura Ranta

¹Department of Anesthesiology, Cardiothoracic and Vascular Anesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland

,

Emmanuelle Scala

¹Department of Anesthesiology, Cardiothoracic and Vascular Anesthesia, Lausanne University Hospital (CHUV), Lausanne, Switzerland

› Institutsangaben

Abstract

Heparin-induced thrombocytopenia (HIT) is a severe, immune-mediated, adverse drug reaction that paradoxically induces a prothrombotic state. Particularly in the setting of cardiac surgery, where full anticoagulation is required during cardiopulmonary bypass, the management of HIT can be highly challenging, and requires a multidisciplinary approach. In this short review, the different perioperative strategies to run cardiopulmonary bypass will be summarized.

Keywords

Heparin-induced thrombocytopenia - cardiac surgery - state of the art

Volltext

Referenzen

References
1 Staibano P, Arnold DM, Bowdish DM, Nazy I. The unique immunological features of heparin-induced thrombocytopenia. Br J Haematol 2017; 177 (02) 198-207
2 Warkentin TE. The paradox of heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7 (09) 1472-1473
3 Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2015; 373 (03) 252-261
4 Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96 (05) 1703-1708
5 Warkentin TE. Laboratory diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol 2019; 41 (Suppl. 01) 15-25
6 Linkins LA, Dans AL, Moores LK. et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e495S-e530S
7 Cuker A, Arepally GM, Chong BH. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018; 2 (22) 3360-3392
8 Pishko AM, Cuker A. Heparin-induced thrombocytopenia in cardiac surgery patients. Semin Thromb Hemost 2017; 43 (07) 691-698
9 Veale JJ, McCarthy HM, Palmer G, Dyke CM. Use of bivalirudin as an anticoagulant during cardiopulmonary bypass. J Extra Corpor Technol 2005; 37 (03) 296-302
10 Koster A, Dyke CM, Aldea G. et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83 (02) 572-577
11 Choxi AA, Patel PA, Augoustides JG. et al. Bivalirudin for cardiopulmonary bypass in the setting of heparin-induced thrombocytopenia and combined heart and kidney transplantation-diagnostic and therapeutic challenges. J Cardiothorac Vasc Anesth 2017; 31 (01) 354-364
12 de Prada Martín B, Gualis Cardona J, Pérez Blanco I, Martínez Comendador JM. Fulminant coagulopathy after bivalirudin use in a patient diagnosed with heparin-induced thrombocytopenia and subject to cardiac bypass surgery [in Spanish]. Rev Esp Anestesiol Reanim 2014; 61 (03) 157-161
13 Hassen K, Maccaroni MR, Sabry H, Mukherjee S, Serumadar S, Birdi I. Management of refractory bleeding post-cardiopulmonary bypass in an acute heparin-induced thrombocytopenia type II renal failure patient who underwent urgent cardiac surgery with bivalirudin (Angiox^®) anticoagulation. Perfusion 2018; 33 (03) 235-240
14 Gatt P, Galea SA, Busuttil W, Grima C, Muscat J, Farrugia Y. Bivalirudin as an alternative anticoagulant for cardiopulmonary bypass during adult cardiac surgery - a change in practice. J Extra Corpor Technol 2017; 49 (01) 49-53
15 Nikolaidis N, Velissaris T, Ohri SK. Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case. Tex Heart Inst J 2007; 34 (01) 115-118
16 Koster A, Buz S, Krabatsch T, Yeter R, Hetzer R. Bivalirudin anticoagulation during cardiac surgery: a single-center experience in 141 patients. Perfusion 2009; 24 (01) 7-11
17 Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology 2018; 128 (02) 390-400
18 Hillebrand J, Sindermann J, Schmidt C, Mesters R, Martens S, Scherer M. Implantation of left ventricular assist devices under extracorporeal life support in patients with heparin-induced thrombocytopenia. J Artif Organs 2015; 18 (04) 291-299
19 Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol 2007; 78 (02) 161-166
20 Tanigawa Y, Yamada T, Matsumoto K, Nakagawachi A, Torikai A, Sakaguchi Y. Non-recovery of ACT in a patient with heparin-induced thrombocytopenia type II during mitral valve replacement using argatroban anticoagulation. J Anesth 2013; 27 (06) 951-955
21 Wilde MI, Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54 (06) 903-924
22 Krauel KO, Furll BO, Warkentin TE. et al. Heparin-induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008; 6 (12) 2160-2167
23 Westphal K, Martens S, Strouhal U. et al. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure. Thorac Cardiovasc Surg 1997; 45 (06) 318-320
24 Koster A, Meyer O, Fischer T. et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 2001; 122 (06) 1254-1255
25 Koster A, Kukucka M, Bach F. et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001; 94 (02) 245-251
26 Palatianos G, Michalis A, Alivizatos P. et al. Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): An 11-year experience. Am J Hematol 2015; 90 (07) 608-617
27 Palatianos GM, Foroulis CN, Vassili MI. et al. Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost. J Thorac Cardiovasc Surg 2004; 127 (02) 548-554
28 Commin PL, Rozec B, Trossaert M, Le Teurnier Y, Fournet X, Blanloeil Y. Use of heparin and platelet GPIIbIIIa inhibitor tirofiban for cardiac surgery in patients for suspicion of heparin-induced thrombocytopenia. Ann Fr Anesth Reanim 2006; 25 (11-12): 1153-1157
29 Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69 (04) 344-350
30 DiSesa VJ, Huval W, Lelcuk S. et al. Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization. Ann Thorac Surg 1984; 38 (05) 514-519
31 Gernhofer YK, Banks DA, Golts E, Pretorius V. Novel use of cangrelor with heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia who require cardiovascular surgery: a case series. Semin Thorac Cardiovasc Surg 2020; 32 (04) 763-769
32 Girgis AM, Golts E, Humber D, Banks DA. Successful use of cangrelor and heparin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia and end-stage renal disease: a case report. A A Pract 2019; 13 (01) 10-12
33 Scala E, Pitta-Gros B, Pantet O. et al. Cardiac surgery successfully managed with cangrelor in a patient with persistent anti-PF4/heparin antibodies 8 years after heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 2019; 33 (11) 3073-3077
34 Seider S, Ross M, Pretorius V, Maus T. The use of cangrelor and heparin for anticoagulation in a patient requiring pulmonary thromboendarterectomy surgery with suspected heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 2019; 33 (04) 1050-1053
35 Scala E, Gerschheimer C, Gomez FJ, Alberio L, Marcucci C. Potential and limitations of the new P2Y12 inhibitor, cangrelor, in preventing heparin-induced platelet aggregation during cardiac surgery: an in vitro study. Anesth Analg 2020; 131 (02) 622-630
36 Welsby IJ, Um J, Milano CA, Ortel TL, Arepally G. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010; 110 (01) 30-35
37 Warkentin TE, Sheppard JA, Chu FV, Kapoor A, Crowther MA, Gangji A. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood 2015; 125 (01) 195-198
38 Anderson D, Ali K, Blanchette V. et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007; 21 (02) (Suppl. 01) S9-S56
39 Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol 2019; 12 (08) 685-698
40 Koster A, Nazy I, Birschmann IE, Smith JW, Sheppard JI, Warkentin TE. High-dose IVIG plus cangrelor platelet “anesthesia” during urgent heparin-CPB in a patient with recent SRA-negative HIT-thrombosis with persisting platelet-activating antibodies. Res Pract Thromb Haemost 2020; 4 (06) 1060-1064